Should I buy Sarepta Therapeutics (SRPT) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Sarepta Therapeutics
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Wedbush | 82 % | +60.1 % | 11 | $34 +57% |
| HC Wainwright & Co. | 80 % | +55.1 % | 15 | $5 -77% |
| Janney Montgomery Scott | 60 % | +27.9 % | 5 | $175 +711% |
| JP Morgan | 60 % | +15.6 % | 15 | $24 +11% |
| Morgan Stanley | 58 % | +12.7 % | 19 | $20 -7% |
| Goldman Sachs | 40 % | +11.8 % | 5 | $19 -12% |
| Citigroup | 50 % | +9.6 % | 12 | $13 -40% |
| Oppenheimer | 36 % | +1.6 % | 11 | $37 +71% |
✅ Reasons to believe
- Median price target $27, i.e. +25% from the current price ($22).
- The most reliable firm on SRPT, Wedbush (82% hit rate, 11 scored calls), targets $34 (call made on January 23, 2026, maturing on January 23, 2027) (+57%) in its most recent call, and $32 (call made on December 9, 2025, maturing on December 9, 2026) (+48%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 7 ratings, 1 is neutral and 3 are sells.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on SRPT
Median target $27 (+25%) · 7 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Sarepta Therapeutics now?
We won't decide for you. The facts: 43% of analysts rate it a buy, median target $27 (+25%), and Wedbush (most reliable on SRPT, 82%) targets $34. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Sarepta Therapeutics?
Not according to analysts: the median target ($27) is still +25% above the current price ($22) (most reliable on SRPT: Wedbush, 82%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Sarepta Therapeutics still worth investing in?
It depends on the gap between the price ($22) and its estimated value: analysts target $27 on median (+25%), with 43% buys (most reliable on SRPT: Wedbush, 82%). Cross-check with their real reliability on SRPT and the cautions above. Information, not advice.
What's the main risk in buying SRPT?
The consensus is not unanimous: of 7 ratings, 1 is neutral and 3 are sells.
→ Go deeper: the full Sarepta Therapeutics profile (consensus, analyst reliability, price target, performance).